Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with R/R B-ALL : A GRAALL study from the DESCAR-T registry.

IF 7.4 1区医学 Q1 HEMATOLOGY

Blood advances Pub Date : 2024-08-29 DOI:10.1182/bloodadvances.2024013962

Florence Rabian, David Beauvais, Tony Marchand, Sabine Furst, Anne Huynh, Eolia Brissot, Sébastien Maury, Ludovic Gabellier, Patrice Chevallier, Michael Loschi, Stephanie Nguyen Quoc, Marie Balsat, Ingrid Lafon, Amandine Fayard, Vincent Camus, Celestine Simand, Niels Moya, Cristina Castilla-Llorente, Magalie Joris, Ana Berceanu, Anne Thiebaut-Bertrand, Véronique Lheritier, Eve Gehlkopf, Gabrielle Roth Guepin, Thibaut Tl Leguay, Nicolas Boissel

引用次数: 0

查看原文本刊更多论文

Brexucabtagene Autoleucel 在成人 R/R B-ALL 患者中的疗效和耐受性：DESCAR-T 登记处的 GRAALL 研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood advances Medicine-Hematology

CiteScore

12.70

自引率

2.70%

发文量

840

期刊介绍： Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.

文献相关原料

公司名称	产品信息	采购帮参考价格